NAION and treatment of erectile dysfunction: reply from Pfizer.
Sobel
R E
RE
Cappelleri
J C
JC
D002243:Carbolines / Q000009:adverse effects; D016022:Case-Control Studies; D003627:Data Interpretation, Statistical; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D008297:Male; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced*; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D000068581:Tadalafil
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D000068677:Sildenafil Citrate